Quick Answer
Cardiff Oncology, Inc. reported Net Income Loss of -$45.85 million for the year ending 2025.
- Cardiff Oncology, Inc. showed a decrease of -0.9% in Net Income Loss from 2024 to 2025.
- This data is from Cardiff Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2003 to 2025 (24 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 24 years of available data (2003 to 2025), Cardiff Oncology, Inc.'s Net Income Loss has declined by 9,420.4%.
- Historical annual values: Fiscal year 2025: -$45.85 million | Fiscal year 2024: -$45.43 million | Fiscal year 2023: -$41.44 million | Fiscal year 2022: -$38.70 million | Fiscal year 2021: -$28.29 million | Fiscal year 2020: -$19.31 million | Fiscal year 2019: -$16.41 million | Fiscal year 2018: -$16.46 million | Fiscal year 2017: -$24.91 million | Fiscal year 2016: -$39.20 million | Fiscal year 2015: -$27.47 million | Fiscal year 2014: -$14.33 million | Fiscal year 2013: -$11.81 million | Fiscal year 2012: -$11.57 million | Fiscal year 2011: -$2.24 million | Fiscal year 2010: -$5.45 million | Fiscal year 2009: -$2.48 million | Fiscal year 2008: -$5.17 million | Fiscal year 2007: -$4.68 million | Fiscal year 2007: -$7.13 million | Fiscal year 2006: -$7.84 million | Fiscal year 2005: -$5.37 million | Fiscal year 2004: -$383.0 thousand | Fiscal year 2003: -$481.6 thousand.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: